Rachael Brake

Zephyr Software (United States) — United States

Medicine · Health Sciences

11h-index399citations76works4.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(23), PI3K/AKT/mTOR signaling in cancer(20), Bladder and Urothelial Cancer Treatments(16), Peptidase Inhibition and Analysis(9), Cancer Mechanisms and Therapy(8)

Publications76 total

Abstract 4640: Identifying novel drivers of drug sensitivity using an AI-enabled composite biomarker - osimertinib sensitivity beyond EGFR
Cancer Research·2025
Clinical update related to the first-in-human trial of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate.
Journal of Clinical Oncology·2024· 9 cited
Abstract C121: Development of CRB-701 (SYS6002): A novel site-specific, Nectin-4 targeting ADC
Molecular Cancer Therapeutics·2023· 3 cited
833 CRB-601, a selective integrin αvβ8-blocking antibody, prevents TGFβ activation, promotes immune cell remodeling, and exhibits potent antitumor activity
Regular and Young Investigator Award Abstracts·2023Open Access
1388 CRB-601, an integrin αvβ8 blocking antibody entering phase I: pre-clinical and translational biomarkers for indication selection
Regular and Young Investigator Award Abstracts·2023Open Access
Novel <scp>cannabinoid receptor 1</scp> inverse agonist <scp>CRB</scp>‐913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the <scp>diet‐induced obesity</scp> mouse model
Obesity·2023· 16 citedOpen Access
Abstract 706: CRB-601, an avβ8 blocking antibody, prevents activation of TGFb and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment
Cancer Research·2023· 3 cited
Supplementary Figure S1 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
2023Open Access
Supplementary Figure S5 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
2023Open Access
Supplementary Table 2 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
2023Open Access
Supplementary Figure S3 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
2023Open Access
Supplementary Figure S6 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
2023Open Access
Supplementary Figure S1 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
2023Open Access
Supplementary Figure S2 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
2023Open Access
Supplementary Figure S4 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
2023Open Access
Supplementary Figure S4 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
2023Open Access
Supplementary Table 1 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
2023Open Access
Supplementary Figure S5 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
2023Open Access
Supplementary Figure S6 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
2023Open Access
Supplementary figure legends from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Oriol Arpí(9), Sílvia Menéndez(9), Natalia Iarchouk(9), Federico Rojo(9), Ana Rovira(9), Joaquim Bellmunt(9), Joan Albanell(8), Ting Chen(7), Shengwu Liu(7), Chengwei Peng(7), Kwan Ho Tang(7), Shougen Cao(7), Johara Chouitar(7), David H. Peng(7), Jiehui Deng(7), Theresa E. Baker(7), Yuanwang Pan(7), Hailin Ding(7), Val Pyon(7), Cassandra Thakurdin(7)